Alnylam Turns To Value-Based Pricing Again For Oxlumo
Executive Summary
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.
You may also be interested in...
Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
With Lumasiran Pediatric Data, Alnylam Hopes For Approvals In All PH1 Patients
Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.
Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports